For tumor therapy, we used a “clinical facsimile” batch with a low differentiation profile (Figure 1D, pie charts on the right) for MDA-MB-231 studies and a research batch for THP1-FRβ and HOS-FRα studies. This evidence concerns the gene FOLR2 and neoplasm.